全文获取类型
收费全文 | 117890篇 |
免费 | 9830篇 |
国内免费 | 264篇 |
专业分类
耳鼻咽喉 | 1084篇 |
儿科学 | 3844篇 |
妇产科学 | 2803篇 |
基础医学 | 15671篇 |
口腔科学 | 2230篇 |
临床医学 | 17714篇 |
内科学 | 21835篇 |
皮肤病学 | 1678篇 |
神经病学 | 10650篇 |
特种医学 | 3198篇 |
外国民族医学 | 2篇 |
外科学 | 12533篇 |
综合类 | 1897篇 |
一般理论 | 129篇 |
预防医学 | 15013篇 |
眼科学 | 1697篇 |
药学 | 8133篇 |
中国医学 | 188篇 |
肿瘤学 | 7685篇 |
出版年
2023年 | 643篇 |
2022年 | 1102篇 |
2021年 | 2169篇 |
2020年 | 1396篇 |
2019年 | 2309篇 |
2018年 | 2675篇 |
2017年 | 1928篇 |
2016年 | 2052篇 |
2015年 | 2438篇 |
2014年 | 3376篇 |
2013年 | 5157篇 |
2012年 | 7548篇 |
2011年 | 7857篇 |
2010年 | 4278篇 |
2009年 | 3852篇 |
2008年 | 7104篇 |
2007年 | 7196篇 |
2006年 | 7139篇 |
2005年 | 6825篇 |
2004年 | 6412篇 |
2003年 | 5936篇 |
2002年 | 5677篇 |
2001年 | 1982篇 |
2000年 | 1811篇 |
1999年 | 2010篇 |
1998年 | 1408篇 |
1997年 | 1149篇 |
1996年 | 1040篇 |
1995年 | 952篇 |
1994年 | 898篇 |
1993年 | 918篇 |
1992年 | 1495篇 |
1991年 | 1371篇 |
1990年 | 1285篇 |
1989年 | 1261篇 |
1988年 | 1158篇 |
1987年 | 1153篇 |
1986年 | 1146篇 |
1985年 | 1080篇 |
1984年 | 1020篇 |
1983年 | 864篇 |
1982年 | 705篇 |
1981年 | 612篇 |
1980年 | 565篇 |
1979年 | 720篇 |
1978年 | 588篇 |
1977年 | 486篇 |
1976年 | 460篇 |
1974年 | 515篇 |
1973年 | 457篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Karl Johnson Katherine W. Saylor Isabella Guynn Karen Hicklin Jonathan S. Berg Kristen Hassmiller Lich 《Genetics in medicine》2022,24(2):262-288
PurposeUnderstanding the value of genetic screening and testing for monogenic disorders requires high-quality, methodologically robust economic evaluations. This systematic review sought to assess the methodological quality among such studies and examined opportunities for improvement.MethodsWe searched PubMed, Cochrane, Embase, and Web of Science for economic evaluations of genetic screening/testing (2013-2019). Methodological rigor and adherence to best practices were systematically assessed using the British Medical Journal checklist.ResultsAcross the 47 identified studies, there were substantial variations in modeling approaches, reporting detail, and sophistication. Models ranged from simple decision trees to individual-level microsimulations that compared between 2 and >20 alternative interventions. Many studies failed to report sufficient detail to enable replication or did not justify modeling assumptions, especially for costing methods and utility values. Meta-analyses, systematic reviews, or calibration were rarely used to derive parameter estimates. Nearly all studies conducted some sensitivity analysis, and more sophisticated studies implemented probabilistic sensitivity/uncertainty analysis, threshold analysis, and value of information analysis.ConclusionWe describe a heterogeneous body of work and present recommendations and exemplar studies across the methodological domains of (1) perspective, scope, and parameter selection; (2) use of uncertainty/sensitivity analyses; and (3) reporting transparency for improvement in the economic evaluation of genetic screening/testing. 相似文献
2.
3.
Karen Kayser Ariel Washington Lesley M. Harris Barbara Head 《Journal of psychosocial oncology》2021,39(1):17-34
Abstract
Purpose
Financial hardship can be a major cause of distress among persons with cancer, resulting in chronic stress and impacting physical and emotional health. This paper provides an analysis of the lived experience of cancer patients’ financial hardship from diagnosis to post-treatment. 相似文献4.
5.
6.
7.
Emeline Colomba Patricia Pautier Fanny Pommeret Alexandra Leary 《Expert review of anticancer therapy》2019,19(6):437-446
Introduction: The landscape of poly (ADP-ribose) polymerase (PARP) inhibition in ovarian cancer is rapidly evolving and becoming increasingly complex. Ovarian cancer is leading therapeutic innovation by providing the proof of concept for DNA repair as a target. Three different PARP inhibitors have now received approvals in the US and Europe in different indications. Subtle but crucial differences can be found among the licensed indications for each PARP inhibitor in terms of histology, type of BRCA mutation (germline and/or somatic), number of prior lines of chemotherapy and whether the indication is in the treatment or maintenance settings.
Areas covered: We review the latest clinical data regarding the PARP inhibitor rucaparib in ovarian cancer, provide an update on the evolving landscape of PARP inhibition in ovarian cancer, and summarize avenues of ongoing and future research.
Expert opinion: All eligible patients should be offered a PARP inhibitor. SOLO1 trial results demonstrated an unprecedented benefit maintenance with PARP inhibitors in first line. Results from trials evaluating PARP inhibitors as maintenance in first line regardless of BRCA status and from trials evaluating combinatorial strategies are eagerly awaited. 相似文献
8.
9.